enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Eli Lilly's tirzepatide cuts heart failure risks, company says

   www.aol.com/news/eli-lillys-tirzepatide-cuts...

   In Lilly’s latest trial, patients who got tirzepatide were 38% less likely to be hospitalized, need to increase their heart failure medication or die because of heart complications, compared to ...

3. Hydralazine/isosorbide dinitrate - Wikipedia

   en.wikipedia.org/wiki/Hydralazine/isosorbide_di...

   A new paper was published on these findings and MedCo filed for a new patent for the drug as a treatment for heart failure specifically in black patients. [ 4 ] [ 7 ] [ 8 ] The new patent and the old patent were then licensed to a company called NitroMed, which ran a clinical called the African-American Heart Failure Trial (A-HeFT), the results ...

4. Sacubitril/valsartan - Wikipedia

   en.wikipedia.org/wiki/Sacubitril/valsartan

   Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure.It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan.

5. Acute decompensated heart failure - Wikipedia

   en.wikipedia.org/wiki/Acute_decompensated_heart...

   The treatment of heart disease is rapidly changing and thus new therapies for acute heart failure treatment are being introduced to save more lives from these massive attacks. [24] Bypass surgery is performed by removing a vein from the arm or leg, or an artery from the chest and replacing the blocked artery in the heart. This allows the blood ...

6. Heart failure - Wikipedia

   en.wikipedia.org/wiki/Heart_failure

   Similarly, the ACC/AHA recommends against using COX-2 inhibitor medications in people with heart failure. [54] Thiazolidinediones have been strongly linked to new cases of heart failure and worsening of pre-existing congestive heart failure due to their association with weight gain and fluid retention. [54]

7. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...